CSL (CSL) Life Sciences Investor Forum summary

Company overview and strategy

• Operates as a global biotech leader with market-leading positions in key therapeutic areas and a workforce of 32,000 across 100+ countries.

• Comprises three main business units: Behring (rare diseases), Plasma (plasma collection), and Seqirus (influenza vaccines), with Behring generating over 70% of FY24 revenue.

• Invested over $5 billion in capital expenditure over five years to expand capacity and support future demand.

• Strategy focuses on targeted innovation, operational efficiency, and leveraging digital technology, including generative AI.

• Maintains a long-term growth mindset, emphasizing disciplined capital allocation and global market leadership.

Operational footprint and market positioning

• Manufacturing plants are located in Switzerland, Australia, the U.S., Germany, and the U.K., with a new facility in Melbourne set to open soon.

• Employs over 19,000 people in the U.S., representing 60% of the global workforce, and has invested $3 billion in U.S. operations over seven years.

• Actively monitoring and mitigating risks related to potential U.S. pharmaceutical tariffs, leveraging a global supply chain.

• Most plasma products for U.S. patients are sourced and manufactured domestically, aligning with U.S. policy objectives.

Financial performance and business highlights

• Reported $8.5 billion in revenue and $2.1 billion NPATA for H1 FY25, both up 5%, with net profit after tax up 7%.

• Behring business grew 10%, driven by immunoglobulins (+15%) and albumin, with improving gross margins.

• New technologies like RECA plasmapheresis machines and iNomogram are enhancing plasma collection efficiency.

• HEMGENIX gene therapy for Hemophilia B shows strong long-term data; ANDEMBRY for HAE is pending FDA approval after approvals in multiple countries.

• Seqirus faced challenges from declining U.S. flu vaccination rates but secured pandemic tenders for avian influenza.